Recent studies have confirmed that approximately 50%–70% of IMT patients have ALK gene rearrangement on chromosome 2p23, resulting in abnormal ALK expression (Siemion et al., 2022; Parra-Herran, 2021). This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.